Jorge Gomez Joins Moderna as Chief Financial Officer

CAMBRIDGE, MA / ACCESSWIRE / April 11, 2022 / Moderna, Inc., (Nasdaq:MRNA) a biotechnology firm revolutionary messenger RNA (mRNA) therapeutics and vaccines these days introduced that Jorge Gomez will be part of Moderna as Main Financial Officer, productive Monday, May well 9, 2022. He will provide on Moderna’s Govt Committee and report to Chief Executive Officer, Stéphane Bancel.

“I am delighted to welcome Jorge to Moderna as our Main Monetary Officer and as a member of the Executive Committee,” claimed Mr. Bancel. “As we develop and scale the company globally, Jorge’s experience major the economic functions of multinational healthcare organizations will be an asset to our group. Jorge’s passion for sustainability and ESG aligns carefully with Moderna’s vision to make corporate accountability a essential element of who we are and what we do. I seem ahead to functioning with Jorge as we proceed to produce on our strategic priorities to in the long run effects human health with mRNA medicines.”

Mr. Gomez joins Moderna from Dentsply Sirona, Inc. (Nasdaq: XRAY) where by he served as Govt Vice President & Main Financial Officer since August 2019. At Dentsply Sirona, he was responsible for major the global finance firm, like strategic finance, FP&A, Accounting, Treasury, Tax, Corporate Audit and Investor Relations, and the Facts Engineering function. In addition, Mr. Gomez was liable for top Dentsply Sirona’s sustainability and ESG system.

Prior to Dentsply Sirona, Mr. Gomez used 13 years at Cardinal Wellbeing (NYSE: CAH), a Fortune 14 organization, wherever he most just lately served as CFO and formerly held positions which includes Professional medical Section CFO, Pharmaceutical Phase CFO, Company Treasurer and Company Controller. Prior to Cardinal Overall health, Mr. Gomez held positions of progressive money and business enterprise management at Typical Motors, such as in New York Town, Singapore, Belgium, and Brazil.

Tale proceeds

“It is a privilege for me to be a part of an organization that is concentrated on establishing transformative medicines to address major community healthcare difficulties worldwide,” explained Mr. Gomez. “I glimpse forward to functioning with the staff on this fantastic mission.”

Mr. Gomez obtained his Grasp of Business Administration from the College of Hartford and his Bachelor of Science in electrical engineering from the Nationwide University of Colombia. Mr. Gomez serves on the Board of Administrators for Xylem, Inc. (NYSE: XYL) and for Pear Therapeutics (Nasdaq: PEAR).

David Meline, Moderna’s current CFO, has made the decision to retire and will continue being with the Company as a marketing consultant to guarantee a sleek changeover of the CFO part to Mr. Gomez.

“I am incredibly thankful to David for acquiring made the decision to come out of retirement in the spring of 2020 to aid us get Moderna ready for commercialization in file time. Moderna was an early-phase advancement, U.S. concentrated business when David joined us. He goes back again into retirement right after acquiring helped renovate Moderna into a world wide business business. He has constructed a fantastic team and powerful economic organization procedures. It has been a pleasure to get the job done with him, and I would like him and his wife a great time.”

About Moderna

In 10 years given that its inception, Moderna has transformed from a research-stage firm advancing applications in the industry of messenger RNA (mRNA), to an organization with a varied scientific portfolio of vaccines and therapeutics across six modalities, a wide intellectual home portfolio in locations which include mRNA and lipid nanoparticle formulation, and an built-in manufacturing plant that enables for the two clinical and industrial production at scale. Moderna maintains alliances with a broad assortment of domestic and abroad governing administration and industrial collaborators. Most just lately, Moderna’s capabilities have arrive alongside one another to let the approved use of a person of the earliest and most powerful vaccines versus the COVID-19 pandemic.

Moderna’s mRNA platform builds on steady advances in essential and utilized mRNA science, delivery technological know-how and producing, and has permitted the enhancement of therapeutics and vaccines for infectious diseases, immuno-oncology, scarce conditions, cardiovascular conditions, and autoimmune conditions. Moderna has been named a best biopharmaceutical employer by Science for the earlier 7 several years. To understand additional, check out www.modernatx.com.

Forward Searching Statements

This push release incorporates forward-looking statements within just the indicating of the Private Securities Litigation Reform Act of 1995, as amended, including pertaining to the Firm’s appointment of Jorge Gomez as Main Fiscal Officer and the retirement of recent Chief Money Officer, David Meline. The ahead-on the lookout statements in this push launch are neither guarantees nor guarantees, and you ought to not place undue reliance on these forward-seeking statements for the reason that they include known and mysterious challenges, uncertainties, and other factors, quite a few of which are past Moderna’s command and which could cause actual success to vary materially from those people expressed or implied by these forward-hunting statements. These pitfalls, uncertainties, and other components include people other threats and uncertainties explained less than the heading “Danger Elements” in Moderna’s most current Yearly Report on Type 10-K submitted with the U.S. Securities and Exchange Fee (SEC) and in subsequent filings built by Moderna with the SEC, which are accessible on the SEC’s site at www.sec.gov. Other than as needed by law, Moderna disclaims any intention or responsibility for updating or revising any ahead-hunting statements contained in this push release in the occasion of new information and facts, long term developments or otherwise. These ahead-seeking statements are primarily based on Moderna’s existing expectations and converse only as of the date hereof.

Moderna Contacts

Media:
Colleen Hussey
Senior Director, Company Communications
617-335-1374
[email protected]

Traders:
Lavina Talukdar
Senior Vice President & Head of Trader Relations
617-209-5834
[email protected]

Source: Moderna, Inc.

Check out source version on accesswire.com:
https://www.accesswire.com/696878/Jorge-Gomez-Joins-Moderna-as-Main-Fiscal-Officer